Haemonetics Co. (NYSE:HAE) Shares Purchased by Zions Bancorporation N.A.

Zions Bancorporation N.A. raised its position in shares of Haemonetics Co. (NYSE:HAE) by 56.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,996 shares of the medical instruments supplier’s stock after acquiring an additional 14,762 shares during the quarter. Zions Bancorporation N.A.’s holdings in Haemonetics were worth $3,201,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Loomis Sayles & Co. L P increased its stake in Haemonetics by 8.1% during the third quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier’s stock worth $13,171,000 after acquiring an additional 12,310 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Haemonetics by 174.5% in the third quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock worth $1,362,000 after acquiring an additional 10,774 shares during the last quarter. Boston Trust Walden Corp grew its stake in shares of Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after purchasing an additional 106,114 shares in the last quarter. FMR LLC boosted its position in shares of Haemonetics by 206.3% during the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier’s stock worth $62,257,000 after acquiring an additional 521,640 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in Haemonetics in the fourth quarter valued at approximately $319,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Stock Performance

HAE stock opened at $64.55 on Tuesday. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The stock has a market capitalization of $3.24 billion, a price-to-earnings ratio of 25.41, a PEG ratio of 1.11 and a beta of 0.43. The stock’s fifty day moving average is $66.99 and its two-hundred day moving average is $74.96.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, research analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Analyst Upgrades and Downgrades

HAE has been the topic of a number of research reports. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. JMP Securities dropped their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research note on Friday, February 7th. Needham & Company LLC cut their price objective on Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. Barrington Research dropped their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. began coverage on shares of Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.